The Annexure

News to 16 October 2026 ·

Desk›Healthcare› Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd

BSE 544210 · NSE EMCURE · ISIN INE168P01015 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹1,871.25

-0.43%

BSE close, 28 August 2026

Market cap

₹35,493.90 cr

19.0 cr shares · Mid cap

Free float

₹7,807.88 cr

as published

P/E · P/B

43.8× · 12.55×

EPS ₹42.72 · BV ₹149.10

FY25-26 rev / PAT

5,243.19 / 732.96

₹ cr, as filed

Filings, window

31

8 selected · 26%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹1,260.10 52-WK HIGH ₹2,047.40 ₹1,871.25 78% of range
Against 52-week high-8.6%
Against 52-week low+48.5%
Day change-0.43%
Size bandMid cap
Index membershipNIFTY 500

Valuation as published by BSE

Earnings per share₹42.72
Price / earnings43.80×
Price / book12.55×
Book value — derived, price ÷ P/B₹149.10
Return on equity28.65%
Operating margin25.13%
Net margin13.79%

Consistency check

P/B ÷ P/E, which must equal ROE
28.65%
ROE as published
28.65%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 1,450.93 200.11 10.55 25.13% 13.79%
Mar-26 · Q 1,467.70 233.70 12.33 27.67% 15.92%
FY25-26 5,243.19 732.96 38.67 24.97% 13.98%

Quarter on quarter

Revenue, quarter on quarter
-1.1%
Net profit, quarter on quarter
-14.4%
Operating margin, quarter on quarter
-254 bps

Disclosure profile 31 filings in the window

0 median 17.0 p75 · 24 sector max 59 31 90th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 24 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Investor Presentation2
Board Outcome1
Change in Management1
Credit Rating1
Order / Contract1
Results1
Scheme of Arrangement1
Selected sub-total8
Procedural
Analyst / Investor Meet9
AGM / EGM3
ESOP Allotment2
General2
Annual Report1
BRSR1
Board Meeting1
Compliance Certificate1
Newspaper Publication1
Record Date1
Trading Window1
Procedural sub-total23
Total31

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 98 trading days

31 filings · 8 selected · busiest 2026-08-06 and 2026-08-07

Filing rhythm · the twelve most recent

2026-09-012026-10-14

SelectedProcedural

Filings

31 in the window · 13 earlier on record

  1. 14 October 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation for Earnings Call - Q2 FY27

    Company Update / Analyst / Investor Meet View filing →

  2. 14 October 2026 ·

    Board Meeting

    Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30, 2026

    Emcure Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial ....

    Board Meeting / Board Meeting View filing →

  3. 12 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  4. 12 October 2026 ·

    Scheme of Arrangement

    Scheme of Arrangement

    Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited - Holding ....

    Company Update / Scheme of Arrangement View filing →

  5. 2 October 2026 ·

    Order / Contract

    Award_of_Order_Receipt_of_Order

    Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulatory Order(s)

    Company Update / Award of Order / Receipt of Order View filing →

  6. 29 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation of Closure of Trading Window

    Insider Trading / SAST / Closure of Trading Window View filing →

  7. 25 September 2026 ·

    Investor Presentation

    Investor Presentation

    Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation

    Company Update / Investor Presentation View filing →

  8. 23 September 2026 ·

    General

    Intimation Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015 - Change In Composition Of The Board Of The Company

    Change in composition of the Board of the Company

    Company Update / General View filing →

  9. 23 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting Results of the 45th Annual General Meeting of the Company along with the consolidated Report of the Scrutinizer

    AGM/EGM / AGM View filing →

  10. 21 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of the 45th Annual General Meeting of the Members of the Company

    AGM/EGM / AGM View filing →

  11. 11 September 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Allotment of 11,400 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 2013

    Company Update / Allotment of ESOP / ESPS View filing →

  12. 1 September 2026 ·

    General

    Intimation Under Regulations 30 And 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Dispatch of letter to the members whose e-mail addresses are not registered with the Company/Depository Participants

    Company Update / General View filing →

  13. 1 September 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of schedule of Investor Meet on Friday, September 04, 2026

    Company Update / Analyst / Investor Meet View filing →

  14. 1 September 2026 ·

    Credit Rating

    Credit Rating

    Reaffirmation of Credit Ratings by CARE Ratings Limited

    Company Update / Credit Rating View filing →

  15. 28 August 2026 ·

    BRSR

    Business Responsibility and Sustainability Reporting (BRSR)

    Business Responsibility and Sustainability Report for the Financial Year 2025-26

    Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

  16. 28 August 2026 ·

    AGM / EGM

    Notice Of The 45Th Annual General Meeting

    Notice of the 45th Annual General Meeting of Emcure Pharmaceuticals Limited

    AGM/EGM / AGM View filing →

  17. 28 August 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    Annual Report of the Company for the Financial Year 2025-26

    Others / Reg. 34 (1) Annual Report View filing →

  18. 25 August 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Allotment of 19,100 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 2013

    Company Update / Allotment of ESOP / ESPS View filing →

  19. 12 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Transcript of Earnings Call - Q1 FY27

    Company Update / Analyst / Investor Meet View filing →

  20. 7 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Analyst/ Investor Meet on Tuesday, September 22, 2026

    Company Update / Analyst / Investor Meet View filing →

  21. 7 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Analyst/ Investor Meet on Thursday, September 17, 2026

    Company Update / Analyst / Investor Meet View filing →

  22. 7 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Analyst/ Investor Meet on Tuesday, September 01, 2026

    Company Update / Analyst / Investor Meet View filing →

  23. 7 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Analyst/ Investor Meet on Tuesday, August 18, 2026

    Company Update / Analyst / Investor Meet View filing →

  24. 7 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Analyst/Investor Meet on Wednesday, August 12, 2026

    Company Update / Analyst / Investor Meet View filing →

  25. 7 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2026

    Company Update / Newspaper Publication View filing →

  26. 6 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Audio recording of Earnings Call - Q1 FY27

    Company Update / Analyst / Investor Meet View filing →

  27. 6 August 2026 ·

    Record Date

    Intimation Of Date Of The 45Th Annual General Meeting And Record Date

    Intimation of date of the 45th Annual General Meeting and Record Date for payment of Final Dividend on Equity Shares for the Financial Year March 31, 2026

    Corp. Action / Record Date View filing →

  28. 6 August 2026 ·

    Change in Management

    Change in Management

    Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Change in composition of the Board of the Company

    Company Update / Change in Management View filing →

  29. 6 August 2026 ·

    Investor Presentation

    Investor Presentation

    Presentation on Unaudited Financial Results for the quarter ended June 30, 2026

    Company Update / Investor Presentation View filing →

  30. 6 August 2026 ·

    Results

    Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026

    Unaudited Financial Results (Standalone and consolidated) for the quarter ended June 30, 2026

    Result / Financial Results View filing →

  31. 6 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On August 06, 2026

    Outcome of Board Meeting held on August 06, 2026

    Board Meeting / Outcome of Board Meeting View filing →

RSS feed for Emcure Pharmaceuticals Ltd · the 50 most recent filings